High-Impact Form 4 Intelligence
Real-time SEC insider trading data with advanced filtering. Free beta.
Total Buys (Filtered)
$0
$0
Total Sells (Filtered)
$2.3M
$2,346,707
| Ticker | Company | Reporting Owner | Date | Value (USD) | Type | Form 4 |
|---|---|---|---|---|---|---|
| STOK |
Stoke Therapeutics, Inc.
|
Director
Sell to Cover
|
2025-12-05 | $267,761x3 | S | Form 4 |
| STOK |
Stoke Therapeutics, Inc.
|
Director
Sell to Cover
|
2025-12-04 | $199,197x2 | S | Form 4 |
| STOK |
Stoke Therapeutics, Inc.
|
Director
Equity Compensation
|
2025-12-03 | $0 | M | Form 4 |
| STOK |
Stoke Therapeutics, Inc.
|
Director
Sell to Cover
|
2025-12-03 | $32,793x2 | S | Form 4 |
| STOK |
Stoke Therapeutics, Inc.
|
Director
Sell to Cover
|
2025-12-02 | $31,748x2 | S | Form 4 |
| STOK |
Stoke Therapeutics, Inc.
|
Director
Equity Compensation
|
2025-12-01 | $0 | M | Form 4 |
| STOK |
Stoke Therapeutics, Inc.
|
Director
Other
|
2025-10-08 | $15,000 | M | Form 4 |
|
STOK
S
Stoke Therapeutics, Inc.
Kaye Edward M. MD
• Director
10b5-1 SellΔOwn -33.7%
2025-10-08
$750,000
|
||||||
| STOK |
Stoke Therapeutics, Inc.
|
Director
10b5-1 SellΔOwn -33.7%
|
2025-10-08 | $750,000 | S | Form 4 |
|
STOK
S
Stoke Therapeutics, Inc.
Kaye Edward M. MD
• Director
10b5-1 SellΔOwn -46.4%
2025-10-03
$1,065,206Large
|
||||||
| STOK |
Stoke Therapeutics, Inc.
|
Director
10b5-1 SellΔOwn -46.4%
|
2025-10-03 | $1,065,206Large | S | Form 4 |
| STOK |
Stoke Therapeutics, Inc.
|
Director
Equity Compensation
|
2024-12-01 | $0 | M | Form 4 |